Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Targeting High Fatality Cancers - Innovation Grant

McGill University

$99,372.00

Validating a promising targeted therapeutic approach in pancreatic cancer

FY 2015-16

Summary
For pancreatic cancer, the rate of diagnosis is almost similar to the rate of mortality because in majority of patients, tumor is discovered in the late stages when it has spread throughout the pancreas. This aggressive behavior of pancreatic cancer gives rise to resistance to conventional treatment approaches. Therefore, there is an urgent need for development of novel treatment strategies against this devastating disease. In this project, my colleagues and I will investigate a novel therapeutic approach through targeting a specific protein in pancreatic cancer cells. We have identified a protein which is overexpressed in pancreatic tumors and inhibition of this protein by specific inhibitors in cell lines models of pancreatic cancer results in cancer cell death. Findings from our previous research are promising; however need validation in animal models of pancreatic cancer. In the current project, we propose various experiments in mouse models of pancreatic cancer to validate relevance of this protein as an appropriate target for treatment of pancreatic cancer. Currently there is no effective treatment against pancreatic cancer, and vast majority of patients have tumors that develop resistance to systemic therapy. Pending validation in this project, our results may help develop a new targeted therapy against pancreatic cancer.
Program
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
341777
Name
Riazalhosseini Yasser
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Targeting High Fatality Cancers Innovation Grant
Projecttitle
Validating a promising targeted therapeutic approach in pancreatic cancer
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$99,372
Cihrequipment2
$0
Programname2
Operating Grant: Targeting High Fatality Cancers - Innovation Grant
Keyworddelim
Mouse Models; Pancreatic Cancer; Pdx; Therapeutic Target Validation
Abstract
For pancreatic cancer, the rate of diagnosis is almost similar to the rate of mortality because in majority of patients, tumor is discovered in the late stages when it has spread throughout the pancreas. This aggressive behavior of pancreatic cancer gives rise to resistance to conventional treatment approaches. Therefore, there is an urgent need for development of novel treatment strategies against this devastating disease. In this project, my colleagues and I will investigate a novel therapeutic approach through targeting a specific protein in pancreatic cancer cells. We have identified a protein which is overexpressed in pancreatic tumors and inhibition of this protein by specific inhibitors in cell lines models of pancreatic cancer results in cancer cell death. Findings from our previous research are promising; however need validation in animal models of pancreatic cancer. In the current project, we propose various experiments in mouse models of pancreatic cancer to validate relevance of this protein as an appropriate target for treatment of pancreatic cancer. Currently there is no effective treatment against pancreatic cancer, and vast majority of patients have tumors that develop resistance to systemic therapy. Pending validation in this project, our results may help develop a new targeted therapy against pancreatic cancer.
Competitiondate
201601
Approvedterm2
1 yr 0 mth
Pinamesdelim
Riazalhosseini, Yasser
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $99,372~ $0~